Behnam Badie
City of Hope Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
7
all conditions, ClinicalTrials.gov
NIH grants tied to them
12
NIH RePORTER
Trial papers in glioblastoma
7
PubMed author-name match
Trials
Studies that name Behnam Badie as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:31 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07544992 · Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade GliomasCity of Hope Medical Center · recruiting · Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma, IDH-Wildtype · principal investigator
- Ph1NCT06815029 · Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant AstrocytomaCity of Hope Medical Center · recruiting · Recurrent Astrocytoma, IDH-Mutant, Grade 3, Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma · principal investigator
- Ph1NCT04214392 · Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive GlioblastomaCity of Hope Medical Center · active not recruiting · Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent WHO Grade II Glioma · principal investigator
- Ph1NCT04003649 · IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBMCity of Hope Medical Center · active not recruiting · Recurrent Glioblastoma, Refractory Glioblastoma · principal investigator
- Ph1NCT03389230 · Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV GliomaCity of Hope Medical Center · active not recruiting · Glioblastoma, Malignant Glioma, Recurrent Glioma · principal investigator
- Ph1NCT02208362 · Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant GliomaCity of Hope Medical Center · active not recruiting · Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent WHO Grade II Glioma · principal investigator
- Ph1NCT01082926 · Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2City of Hope Medical Center · completed · Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Meningioma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:31 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Development of Small Molecule Inhibitors and Biologic Agents for Treatment of Glioblastoma Using Intracerebral Microdialysis and Signatures of VulnerabilityU19CA264512 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 2021 to 2026 · $680,856 awarded in 2026Same name and institution; not confirmed by an ID
- Improving Glioma Immunotherapy Efficacy by Regulating Tumor InflammationR01NS134116 · NINDS · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 2023 to 2026 · $571,835 awarded in 2026Same name and institution; not confirmed by an ID
- Novel Neurosurgical Device for Evacuation of Intracerebral HematomaR01NS143100 · NINDS · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 2025 to 2026 · $633,561 awarded in 2026Same name and institution; not confirmed by an ID
- Targeting Glioblastoma with Multifunctional Anti-RAGE OligonucleotidesR01NS143106 · NINDS · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 2026 · $548,395 awarded in 2026Same name and institution; not confirmed by an ID
- Clinical Evaluation of Chlorotoxin-redirected Chimeric Antigen Receptor (CAR) T cells for Treatment of GlioblastomaR01CA254271 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 2020 to 2024 · $711,759 awarded in 2024Same name and institution; not confirmed by an ID
- Clinical evaluation of IL13Ra2-targeted CAR T cell therapy in combination with nivolumab in patients with recurrent malignant gliomaR01CA236500 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 2019 to 2024 · $809,915 awarded in 2024Grant number is on one of their registry trials
- GMP Manufacturing CoreP30CA033572 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 2020 to 2021 · $173,519 awarded in 2021Grant number is on one of their registry trials
- Role of Receptor for Advanced Glycation End Product (RAGE) Pathway in Brain TumorsR01CA155769 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 2011 to 2021 · $410,877 awarded in 2021Same name and institution; not confirmed by an ID
- Phase 1 Study of Cellular Immunotherapy Using Optimized IL13Ra2 Specific CAR T cells for the Treatment of Malignant Glioma R01FD005129 · FDA · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 2015 to 2017 · $200,000 awarded in 2017Same name and institution; not confirmed by an ID
- Novel Cell Delivery Method for Brain Tumor TherapyR21CA189223 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 2014 to 2015 · $230,375 awarded in 2015Same name and institution; not confirmed by an ID
- Dynamic Magnetic Targeting of Activated Brain Macrophages for Glioma TherapyR21NS081594 · NINDS · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 2013 to 2014 · $195,117 awarded in 2014Same name and institution; not confirmed by an ID
- Application of Carbon Nanotubes for Macrophage Activation in Brain Tumor ModelsR21CA131765 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 2009 to 2010 · $182,600 awarded in 2010Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name in glioblastoma, ranked by citations from NIH iCite, fetched 2026-11-12 11:31 UTC. The ranking covers the 200 most relevant of 7 PubMed records, and a shared surname and initials can bring in a namesake. All 7 on PubMed
- Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.N Engl J Med · 20161,539 citationsRCR 47.1
- Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.Clin Cancer Res · 2015653 citationsRCR 18.8
- Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial.Nat Med · 2024328 citationsRCR 38.8
- Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma.Neuro Oncol · 2016147 citationsRCR 4.9
- Off-the-shelf, steroid-resistant, IL13Rα2-specific CAR T cells for treatment of glioblastoma.Neuro Oncol · 2022144 citationsRCR 9.1
- Chlorotoxin-directed CAR T cell therapy for recurrent glioblastoma: Interim clinical experience demonstrating feasibility and safety.Cell Rep Med · 202520 citationsRCR 4.5
- An intracerebral microdialysis study to determine the neuropharmacokinetics of eribulin in patients with metastatic or primary brain tumors.Cancer Chemother Pharmacol · 20242 citationsRCR 0.3